SG11201900665VA - Cannabis composition - Google Patents

Cannabis composition

Info

Publication number
SG11201900665VA
SG11201900665VA SG11201900665VA SG11201900665VA SG11201900665VA SG 11201900665V A SG11201900665V A SG 11201900665VA SG 11201900665V A SG11201900665V A SG 11201900665VA SG 11201900665V A SG11201900665V A SG 11201900665VA SG 11201900665V A SG11201900665V A SG 11201900665VA
Authority
SG
Singapore
Prior art keywords
international
bay
western australia
perth
pct
Prior art date
Application number
SG11201900665VA
Other languages
English (en)
Inventor
Harry Karelis
Mara Gordon
Stewart Smith
Stewart Washer
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61072172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201900665V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of SG11201900665VA publication Critical patent/SG11201900665VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
SG11201900665VA 2016-08-03 2017-08-03 Cannabis composition SG11201900665VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662370304P 2016-08-03 2016-08-03
PCT/AU2017/050814 WO2018023163A1 (en) 2016-08-03 2017-08-03 Cannabis composition

Publications (1)

Publication Number Publication Date
SG11201900665VA true SG11201900665VA (en) 2019-02-27

Family

ID=61072172

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900665VA SG11201900665VA (en) 2016-08-03 2017-08-03 Cannabis composition

Country Status (15)

Country Link
US (2) US11779562B2 (https=)
EP (1) EP3493798A4 (https=)
JP (1) JP2019523283A (https=)
KR (2) KR20190035791A (https=)
CN (1) CN109843287A (https=)
AU (4) AU2017307643B2 (https=)
BR (1) BR112019001852A2 (https=)
CA (1) CA3031810A1 (https=)
CL (1) CL2019000270A1 (https=)
CO (1) CO2019001044A2 (https=)
IL (2) IL264461B2 (https=)
MX (1) MX386620B (https=)
PE (1) PE20200726A1 (https=)
SG (1) SG11201900665VA (https=)
WO (1) WO2018023163A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018023166A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
SG11201900665VA (en) 2016-08-03 2019-02-27 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
NZ757591A (en) * 2017-03-30 2026-03-27 Ojai Energetics Pbc Methods and compositions for enhancing health
BR112019026877A2 (pt) 2017-06-19 2020-06-30 Zelda Therapeutics Operations Pty Ltd composições para distúrbios do sono e tratamentos do mesmo
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
WO2019173242A1 (en) * 2018-03-04 2019-09-12 Cmg Partners, Inc. Enhanced smokable cannabis-based therapeutic product for treatment of sleep disorders and chronic pain and method for making same
CA3103938A1 (en) * 2018-06-15 2019-12-19 California Cannabinoids Compositions and methods for treatment of narcolepsy and related disorders
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
WO2020168073A1 (en) * 2019-02-13 2020-08-20 Caras Jim Composition comprising hydrolyzed collagen and cannabidiol and use thereof
NL2022616B1 (en) 2019-02-21 2020-09-18 Patrick Alexander Unger Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia
US11554098B2 (en) 2019-05-03 2023-01-17 HFL Partners, LLC Compositions comprising molecularly separated cannabinoids and terpene blends and methods of producing
CN118161552A (zh) * 2019-12-19 2024-06-11 史蒂文·罗斯斯坦 富含多酚化合物的提取物以及相关方法
US11000818B1 (en) * 2019-12-27 2021-05-11 Cresco Labs Llc Post processing method for cannabis oil
IT202000017137A1 (it) * 2020-07-15 2022-01-15 Linnea Sa Estratti di cannabis sativa e loro usi
DK181329B1 (en) * 2021-05-04 2023-08-16 Cs Medica As Nasal sleep spray composition, method for its provision, and receptacle and kit comprising said composition
US20230000935A1 (en) * 2021-07-03 2023-01-05 Joseph Anthony Bidwell Extract Infused Cannabis Flower, Natural preservation of Cannabis Flower and the method therefor
US20250144122A1 (en) * 2023-11-06 2025-05-08 Roberto Colon-Cruz Scent-Changing Ointment & Method of Making The Same
KR20260005072A (ko) * 2024-07-01 2026-01-09 피비엘바이오랩 주식회사 신규 유산균 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2400320B (en) 2001-05-04 2005-06-08 Gw Pharma Ltd Cannabinoid-rich extracts
JP4411117B2 (ja) * 2004-03-25 2010-02-10 エスエス製薬株式会社 睡眠改善医薬組成物
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
JP2007246428A (ja) * 2006-03-15 2007-09-27 Nature Technology Inc 植物精油成分を有効成分とする経皮吸収型睡眠覚醒用医薬組成物、その組成物を含有する経皮吸収型睡眠覚醒用医薬製剤、及びこれらの製造方法
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
KR20110120153A (ko) * 2010-04-28 2011-11-03 고려대학교 산학협력단 리모넨을 함유하는 아데노신 Ａ2ａ 수용체 작용제
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
WO2013165251A1 (en) 2012-05-03 2013-11-07 Echo Pharmaceuticals B.V. Cannabis plant isolate comprising /\9-tetrahydrocannabinol and a method for preparing such an isolate
CA2895805A1 (en) 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
EP2968259B1 (en) 2013-03-14 2022-09-14 SC Laboratories Inc. Bioactive concentrates and uses thereof
WO2014145490A2 (en) * 2013-03-15 2014-09-18 Biotech Institute, Llc Breeding, production, processing and use of specialty cannabis
US10265292B2 (en) 2013-09-18 2019-04-23 The Werc Shop, LLC Terpene-based compositions, processes methodologies
HRP20221172T1 (hr) * 2013-10-29 2023-02-03 Biotech Institute, Llc Uzgoj, proizvodnja, prerada i uporaba specijalnog sinsemilla kanabisa
WO2015068052A2 (en) 2013-10-31 2015-05-14 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
EP3160445B1 (en) * 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
AU2015279612A1 (en) 2014-06-27 2017-02-02 Kenton L. Crowley Buccal and sublingual cannabinoid formulations and method of making the same
AU2015308546A1 (en) * 2014-08-25 2017-04-13 Clk Consult V/ Carsten Leonhard Knudsen Device with compositions for delivery to the lungs, the oral mucosa and the brain
BR122021018502B1 (pt) * 2014-10-21 2022-05-03 United Cannabis Corp Formulação de canabinoide líquida
MX395015B (es) 2014-12-12 2025-03-24 Ojai Energetics Pbc Composiciones microencapsuladas de cannabinoides
CA2974292C (en) 2015-01-31 2024-04-16 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
AU2016225026A1 (en) 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
SG11201900665VA (en) 2016-08-03 2019-02-27 Zelda Therapeutics Operations Pty Ltd Cannabis composition
JP2019523282A (ja) 2016-08-03 2019-08-22 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
WO2018023166A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
BR112019026877A2 (pt) 2017-06-19 2020-06-30 Zelda Therapeutics Operations Pty Ltd composições para distúrbios do sono e tratamentos do mesmo
AU2018101357B4 (en) 2017-09-15 2022-03-17 Zelira Therapeutics Operations Pty Ltd Composition and method for treating autism
AU2018100924A4 (en) 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
MX2022015799A (es) 2020-06-12 2023-04-11 Zelira Therapeutics Operations Pty Ltd Composicion y metodo para el tratamiento del dolor cronico.
AU2021376539A1 (en) 2020-11-06 2023-06-15 Zelira Therapeutics Operations Pty Ltd Cannabinoid encapsulation technology

Also Published As

Publication number Publication date
AU2019253841A1 (en) 2019-11-14
PE20200726A1 (es) 2020-07-21
AU2019253841B2 (en) 2021-07-01
JP2019523283A (ja) 2019-08-22
BR112019001852A2 (pt) 2019-05-07
IL296008A (en) 2022-10-01
IL296008B1 (en) 2024-05-01
CA3031810A1 (en) 2018-02-08
EP3493798A4 (en) 2020-05-06
AU2018100923B4 (en) 2018-09-27
KR20190035791A (ko) 2019-04-03
US20230414559A1 (en) 2023-12-28
MX2019001285A (es) 2019-06-13
CN109843287A (zh) 2019-06-04
WO2018023163A1 (en) 2018-02-08
AU2021240297B2 (en) 2023-08-24
IL264461B2 (en) 2024-09-01
CL2019000270A1 (es) 2019-10-04
EP3493798A1 (en) 2019-06-12
US20220347155A1 (en) 2022-11-03
AU2017307643B2 (en) 2019-07-25
CO2019001044A2 (es) 2019-04-30
MX386620B (es) 2025-03-19
US11779562B2 (en) 2023-10-10
IL264461A (en) 2019-02-28
IL264461B1 (en) 2024-05-01
IL296008B2 (en) 2024-09-01
AU2021240297A1 (en) 2021-10-28
AU2018100923A4 (en) 2018-08-09
AU2017307643A1 (en) 2018-07-05
KR20210013645A (ko) 2021-02-04
AU2018100923C4 (en) 2019-10-31
US12239628B2 (en) 2025-03-04

Similar Documents

Publication Publication Date Title
SG11201900665VA (en) Cannabis composition
SG11201900596XA (en) Cannabis composition
SG11201900501RA (en) Cannabis composition
SG11201907427YA (en) Engineered transferrin receptor binding polypeptides
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201906885TA (en) Methods for the administration of certain vmat2 inhibitors
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201804118VA (en) Compositions comprising bacterial strains
SG11201804211YA (en) Compositions comprising bacterial strains
SG11201804368QA (en) Storage assembly for prosthetic valve
SG11201907435PA (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
SG11201909561RA (en) Octree-based convolutional neural network
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201902949PA (en) Pharmaceutical compositions and methods of treating cardiovascular diseases
SG11201908092RA (en) Anti-tigit antigen-binding proteins and methods of use thereof
SG11201804589TA (en) Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201806127XA (en) Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate